# MYOMO, INC. (MYO)

Informational only - not investment advice.

CIK: 0001369290
SIC: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies](/industry/3842/)
Latest 10-K filed: 2026-03-09
SEC page: https://www.sec.gov/edgar/browse/?CIK=1369290
Filing source: https://www.sec.gov/Archives/edgar/data/1369290/000119312526098531/myo-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-09 · accession 0001193125-26-098531 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001369290.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 40,928,042 USD | 2025 | verified |
| Net income | -15,573,884 USD | 2025 | verified |
| Assets | 38,636,573 USD | 2025 | verified |
| Free cash flow | -16,253,701 USD | 2025 | computed |
| Net margin | -38.05% | 2025 | computed |
| Operating margin | -35.19% | 2025 | computed |
| Revenue YoY | +25.73% | 2025 | computed |
| ROE | -136.57% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | MYO | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -38.1% | 7.2% | 8 | 13 |
| Operating margin | -35.2% | 11.0% | 8 | 13 |
| Revenue growth | 25.7% | 7.4% | 100 | 14 |
| FCF margin | -39.7% | 7.7% | 8 | 14 |
| ROE | -136.6% | -1.9% | 0 | 14 |
| ROA | -40.3% | -1.9% | 15 | 14 |
| Liabilities / equity | 2.39 | 0.59 | 92 | 14 |
| Current ratio | 3.30 | 2.58 | 69 | 14 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 40928042 | USD | 2025 | 2026-03-09 |
| Net income | -15573884 | USD | 2025 | 2026-03-09 |
| Assets | 38636573 | USD | 2025 | 2026-03-09 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-09. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001369290.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  |  | 2,444,104 | 3,837,730 | 7,583,371 | 13,856,374 | 15,555,229 | 19,241,158 | 32,551,199 | 40,928,042 |
| Net income | -3,617,022 | -12,097,479 | -10,316,739 | -10,713,009 | -11,563,911 | -10,372,329 | -10,721,022 | -8,147,565 | -6,183,729 | -15,573,884 |
| Operating income | -3,275,002 | -6,548,114 | -10,528,417 | -10,795,003 | -10,502,686 | -10,268,065 | -10,672,204 | -8,231,549 | -6,206,698 | -14,401,847 |
| Gross profit | 821,113 | 1,053,586 | 1,715,825 | 2,416,963 | 4,982,996 | 10,312,277 | 10,253,096 | 13,182,383 | 23,185,343 | 26,888,324 |
| Diluted EPS |  |  |  |  |  | -1.89 | -1.52 | -0.28 | -0.16 | -0.37 |
| Operating cash flow | -3,202,670 | -6,153,419 | -9,606,310 | -10,341,817 | -9,032,896 | -9,547,695 | -10,233,542 | -6,172,764 | -3,289,904 | -14,511,454 |
| Capital expenditures | 1,865 | 67,002 | 126,867 | 51,991 | 45,752 | 326,462 | 111,793 | 145,816 | 1,360,125 | 1,742,247 |
| Assets | 1,658,252 | 13,974,992 | 8,281,572 | 6,598,693 | 14,709,782 | 20,095,412 | 10,162,006 | 14,581,568 | 42,244,079 | 38,636,573 |
| Liabilities | 6,516,467 | 1,529,214 | 1,855,687 | 4,773,985 | 3,144,408 | 4,686,281 | 3,802,641 | 5,592,218 | 17,530,022 | 27,233,106 |
| Stockholders' equity | -17,530,456 | 12,445,778 | 6,425,885 | 6,425,885 | 11,565,374 | 15,409,131 | 6,359,365 | 8,989,350 | 24,714,057 | 11,403,467 |
| Cash and cash equivalents | 797,174 | 12,959,373 | 6,540,794 | 4,465,455 | 12,241,261 | 15,524,378 | 5,345,967 | 6,871,306 | 24,372,373 | 14,132,027 |
| Free cash flow | -3,204,535 | -6,220,421 | -9,733,177 | -10,393,808 | -9,078,648 | -9,874,157 | -10,345,335 | -6,318,580 | -4,650,029 | -16,253,701 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  | -74.86% | -68.92% | -42.34% | -19.00% | -38.05% |
| Operating margin |  |  |  |  | -138.50% | -74.10% | -68.61% | -42.78% | -19.07% | -35.19% |
| Return on equity |  | -97.20% | -160.55% | -166.72% | -99.99% | -67.31% | -168.59% | -90.64% | -25.02% | -136.57% |
| Return on assets |  | -86.57% | -124.57% | -162.35% | -78.61% | -51.62% | -105.50% | -55.88% | -14.64% | -40.31% |
| Liabilities / equity |  | 0.12 | 0.29 | 0.74 | 0.27 | 0.30 | 0.60 | 0.62 | 0.71 | 2.39 |
| Current ratio | 0.38 | 9.32 | 4.24 | 1.58 | 5.03 | 4.46 | 2.56 | 2.49 | 3.22 | 3.30 |

## As-reported value updates

1 tracked difference above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/MYO/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001369290.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.40 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.11 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.04 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  | -1,014,150 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 5,079,523 |  | -0.06 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 4,756,383 | -2,460,104 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 3,754,389 | -3,835,632 | -0.10 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 |  | -3,835,632 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 7,520,767 |  | -0.03 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 |  | -1,121,607 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 9,207,586 |  | -0.03 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 12,068,457 | -260,081 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 9,831,814 | -3,465,058 | -0.08 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 |  | -3,465,058 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 9,652,234 |  | -0.11 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 |  | -4,631,972 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 10,090,699 |  | -0.09 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 11,353,296 | -3,813,938 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 10,113,288 | -3,009,399 | -0.07 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 |  | -3,009,399 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 11,704,565 |  | -0.09 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from MYO's latest 10-K: [/company/MYO/business/](/company/MYO/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from MYO's latest 10-K: [/company/MYO/risk-factors/](/company/MYO/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1369290/000119312526335149/myo-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-05
Report date: 2026-06-30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes contained elsewhere in this Quarterly Report on Form 10-Q and in our other Securities and Exchange Commission filings. The following discussion may contain predictions, estimates, and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors”, “Cautionary Statement Regarding Forward-Looking Statements” and elsewhere in this Quarterly Report on Form 10-Q and those described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2025. These risks could cause our actual results to differ materially from any future performance suggested below.

Overview

We are a wearable medical robotics platform company, specializing in myoelectric braces, or orthotics, for people with neuromuscular disorders. We develop and market the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or deformed arm to enable and improve functional activities of daily living (“ADLs”), in the home and community. It is custom constructed by a trained professional during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help regain function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders.

We advertise on television and through social media. In addition, we perform in-services for therapists and physicians to generate referrals under a new program we refer to as MyoConnect, and we directly educate and inform those individuals who are potential candidates for our products. Once the prospective patient contacts us or is referred to us through our MyoConnect program, either our trained clinical staff or a trained O&P provider will evaluate the patient for their suitability as a candidate. Initial evaluations by our trained clinical staff are often initially conducted using telehealth techniques, followed by an in-person clinical evaluation of the candidate. Prior to obtaining authorizations from commercial insurance companies or delivering to a patient with Medicare Part B, the patient’s medical records are collected and reviewed to make sure the device is medically necessary for their condition and a prescription is always obtained from a physician. Once these documents are obtained, if the patient has Medicare Advantage or other commercial insurance, a pre-authorization request is submitted to the patient’s insurer. If we receive a pre-authorization, we proceed to measure the patient’s arm, a process we call “shape capture”. In many cases, shape capture is done using a remote measurement kit supplied to the patient. If the patient is covered by Medicare Part B, no pre-authorization is required, and we can move directly to taking measurements of the patient's arm. We then use those measurements to 3D print orthotic parts, which are used to fabricate the MyoPro, and then deliver it to the patient. Since we are directly providing the device to the patient and then billing insurance ourselves, we refer to this process as direct billing. We also call on hospitals and O&P practices in the United States, Europe and Australia that provide our products to their patients as well as generate indirect sales. The MyoPro product line has been approved by the VA system for impaired veterans, and over 130 VA facilities have ordered devices for their patients.

Our myoelectric orthoses have been clinically shown in peer reviewed published research studies to help regain the ability to complete functional tasks by supporting the affected joint and enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals. Our technology was originally developed at MIT in collaboration with medical experts affiliated with Harvard Medical School. Myomo was incorporated in 2004.

Other historical milestones include:

•
In 2012, we introduced the MyoPro. The primary business focus shifted from developing devices that were designed for rehabilitation therapy and sold to hospitals to providing an assistive device through O&P providers to patients who are otherwise impaired for use at home, work, and in the community that facilitates ADLs.

•
During 2015, we extended our basic MyoPro for the elbow with the introduction of the MyoPro Motion W, a multi-articulated non-powered wrist and the MyoPro Motion G, which includes a powered grasp. The MyoPro Motion W allows the user to use their sound arm to adjust the device and then, for instance, open a refrigerator door, carry a shopping bag, hold a cell phone, or stabilize themselves to avoid a fall and potential injury. The MyoPro Motion G model allows users with severely weakened or clenched hands, such as seen in certain stroke survivors, to open and close their hands and perform a large number of ADLs.

•
On June 9, 2017, we completed our initial public offering (“IPO”) and a private offering concurrent with the IPO, generating net proceeds of $6.9 million in the aggregate.

•
On July 31, 2017, we met the criteria to apply the CE Mark for the MyoPro. This has enabled us to sell the MyoPro to individuals in the European Union (the “EU”).

•
In November 2018, we announced that the Centers for Medicare and Medicaid Services, (“CMS”), had published two new codes (L8701, L8702) pursuant to our application for Healthcare Common Procedure Coding System (“HCPCS”) codes which become effective in early 2019. The assignment of the unique L-Codes, if followed by appropriate payment terms, should have the effect of offering greater access to the MyoPro for Medicare beneficiaries.

•
In 2019, we transitioned our business to become a direct provider of the MyoPro to patients and bill insurance companies directly.

19

•
In July 2021, we became accredited as a Medicare provider.

•
In January 2022, we introduced MyoPro 2+ and began in-house fabrication of the device.

•
On November 1, 2023, CMS issued a final rule that resulted in a change in the benefit category associated with the products billed under the HCPCS codes for our products from durable medical equipment rental to a brace, which would permit reimbursement of MyoPro sales on a lump sum basis. The rule became effective on January 1, 2024

•
On February 29, 2024, CMS published final payment determinations for the HCPCS codes describing our products which are L8701, for the MyoPro Motion W, and L8702, for the MyoPro Motion G, which became effective on April 1, 2024. These fees were subsequently updated to approximately $34,970 for the Motion W and approximately $68,800 for the Motion G, effective January 1, 2026. These fees are subject to annual inflationary adjustments.

•
On April 30, 2025, we introduced an enhanced version of our flagship product, now known as the MyoPro 2X in the United States.

•
On March 23, 2026, we introduced a mobile application to be used with the MyoPro, replacing the use of an external laptop.

Recent Developments

Term Loan Facility

On November 4, 2025 (“the Closing Date”), we entered into a Loan and Security Agreement with Avenue Capital Management II, L.P., as administrative agent and collateral agent and Avenue Venture Opportunities Fund II, L.P., as a lender (together "Avenue"), which provides us $17.5 million in committed funding under two tranches. The first tranche of $12.5 million was funded on the Closing Date. The remaining $5.0 million becomes available at our discretion between 12 and 18 months from the Closing Date, subject to maintaining compliance with covenants. We are paying interest only on the term loan for a period of 18 months from the Closing Date, which could be extended to 24 months if we borrowed under the second tranche. After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments. The term loan matures on June 1, 2029. Proceeds from this loan were used to repay the outstanding borrowings under the credit facility with Silicon Valley Bank and to pay fees and expenses, with the remainder being used for general corporate purposes.

China Joint Venture

In November 2025, we were notified that Ryzur Medical filed for bankruptcy in China and is in the process of being liquidated. As a result, the operations of the JV Company are now severely limited. Efforts to find another lead investor have not materialized. As a result, we notified the parties on July 24, 2026 that we are terminating the joint venture. We do not expect to receive any proceeds from liquidation of the JV Company and there is no impact to our financial statements from the termination of the joint venture for the three and six months ended June 30, 2026.

Results of Operations

We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue in 2026. Our financial performance in 2025 reflected our ability to be reimbursed by Medicare for providing the MyoPro to their beneficiaries, as well as challenges around marketing efficiency and patient acquisition which increased cost per pipeline add. Our plan for 2026 is to begin to pivot away from relying on direct to patient advertising to generate revenues and invest in generating revenues from recurring patient sources, including the MyoConnect referral program and from O&P providers in the U.S. and Germany, while implementing marketing initiatives to reduce cost per pipeline add in the direct billing channel and minimizing the growth of fixed expenses.

The following table sets forth our revenue, cost of revenue, gross profit and gross margin for each of the periods presented.

[[GREPCENT_TABLE]]
[["","For the Three Months Ended June 30,","Period- to-Period Change","For the Six Months Ended June 30,","Period- to-Period Change"],["","2026","2025","$","%","2026","2025","$","%"],["Revenue","$11,704,565","$9,652,234","$2,052,331","21%","$21,817,853","$19,484,048","2,333,805","12%"],["Cost of revenue","3,262,017","3,600,061","(338,044)","(9)%","6,473,698","6,822,246","(348,548)","(5)%"],["Gross profit","$8,442,548","$6,052,173","$2,390,375","39%","$15,344,155","$12,661,802","$2,682,353","21%"],["Gross margin %","72.1%","62.7%","","9.4%","70.3%","65.0%","","5.3%"]]
[[/GREPCENT_TABLE]]

20

Revenues

We derive revenue primarily from providing devices directly to patients and billing insurance companies or Medicare directly. We also sell our products to O&P providers in the U.S., Europe and Australia, to the VA, and to rehabilitation hospitals. Though we increasingly provide devices directly to patients, we sometimes utilize the clinical services of O&P providers for which they are paid a fee.

We expect that our revenues will continue to grow in 2026, primarily as a result of investments to grow revenues from recurring patient sources, including generating patient referrals under our MyoConnect program, as well as from O&P practices in the U.S. and Germany, which we expect to increase operating leverage and reduce our dependence on advertising-driven direct-to-patient revenues.

Total revenue increased by approximately $2.1 million and $2.3 million, or 21% and 12%, for the three and six months ended June 30, 2026, respectively, as compared to the same periods in 2025. Higher revenues in the three and six months ended June 30, 2026 were due to a higher number of revenue units and a higher average sales price. Revenues by channel for the three and six months ended June 30, 2026 and 2025 were as follows:

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1369290/000119312526098531/myo-20251231.htm
Complete FY 2025 MD&A: /company/MYO/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-09
Report date: 2025-12-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements and the related notes contained elsewhere in this Annual Report on Form 10-K and in our other SEC filings. The following discussion may contain predictions, estimates, and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors” and elsewhere in this Annual Report on Form 10-K. These risks could cause our actual results to differ materially from any future performance suggested below.

Overview

We are a wearable medical robotics company, specializing in myoelectric braces, or orthotics, for people with neuromuscular disorders. We develop and market the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or deformed arm to enable and improve functional activities of daily living, or ADLs, in the home and community. It is custom constructed by a trained professional during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help regain movement in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders.

We advertise on television and through social media. In addition, we perform in-services for therapists and physicians to generate referrals under a new program we refer to as MyoConnect, and we directly educate and inform those individuals who are potential candidates for our products. Once the prospective patient contacts us or is referred to us through our MyoConnect program, either our trained clinical staff or a trained O&P provider will evaluate the patient for their suitability as a candidate. Initial evaluations by our trained clinical staff are conducted using telehealth techniques, followed by an in-person clinical evaluation of the candidate. Prior to obtaining authorizations from commercial insurance companies or delivering to a patient with Medicare Part B, the patient’s medical records are collected and reviewed to make sure the device is appropriate for their condition and a prescription is always obtained from a physician. Once these documents are obtained, if the patient has Medicare Advantage or other commercial insurance, a pre-authorization request is submitted to the patient’s insurer. If we receive a pre-authorization, we proceed to measure the patient’s arm a process we call shape capture. In many cases, shape capture is done using a remote measurement kit supplied to the patient. If the patient is covered by Medicare Part B, no pre-authorization is required and we can move directly to taking measurements of the patient's arm. We then use those measurements to 3D print orthotic parts, which are used to fabricate the MyoPro, and then deliver it to the patient. Since we are directly providing the device to the patient and then billing insurance ourselves, we refer to this process as direct billing. We also call on hospitals and O&P practices in the United States, Europe and Australia that provide our products to their patients as well as generate indirect sales. The MyoPro product line has been approved by the VA system for impaired veterans, and over 130 VA facilities have ordered devices for their patients.

Our myoelectric orthoses have been clinically shown in peer reviewed published research studies to help regain the ability to complete functional tasks by supporting the affected joint and enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals.

Our technology was originally developed at MIT in collaboration with medical experts affiliated with Harvard Medical School. Myomo was incorporated in 2004.

Other milestones in our history include:

•
In 2012, we introduced the MyoPro, the primary business focus shifted during this time period, from devices which were designed for rehabilitation therapy and sold to hospitals, to providing an assistive device through O&P providers to patients who are otherwise impaired for use at home, work, and in the community that facilitates activities of daily living or ADLs.

•
During 2015, we extended our basic MyoPro for the elbow with the introduction of the MyoPro Motion W, a multi-articulated non-powered wrist and the MyoPro Motion G, which includes a powered grasp. The MyoPro Motion W allows the user to use their sound arm to adjust the device and then, for instance, open a refrigerator door, carry a shopping bag, hold a cell phone, or stabilize themselves to avoid a fall and potential injury. The MyoPro Motion G model allows users with severely weakened or clenched hands, such as seen in certain stroke survivors, to open and close their hands and perform a large number of ADLs.

48

Table of Contents

•
On June 9, 2017, we completed our initial public offering, or IPO, and a private offering concurrent with the IPO, generating net proceeds of $6.9 million in the aggregate.

•
On July 31, 2017, we met the criteria to apply the CE mark for the MyoPro under the EU MDD. The EU MDR repealed and replaced the EU MDD and became applicable on May 26, 2021, and we therefore worked with our EU-Authorized Representative to ensure all EU MDR requirements were met, which enabled us to establish a new declaration of conformity under the EU MDR to allow continued to CE mark application. This has enabled us to sell the MyoPro to individuals in the EU.

•
In November 2018, we announced that the CMS had published two new codes (L8701, L8702) that describe our products, pursuant to our application for HCPCS codes which become effective in early 2019. At that time, our products were classified as durable medical equipment rental at that time.

•
In 2019 we transitioned our business to become a direct provider of the MyoPro to patients and bill insurance companies directly.

•
In July 2021, we announced that we became accredited as a Medicare provider.

•
In January 2022, we introduced the MyoPro 2+ and began in-house fabrication of the device.

•
On November 1, 2023, CMS issued a final rule that resulted in a change in the benefit category associated with products billed under the HCPCS codes for our products from durable medical equipment rental to a brace, which would permit reimbursement of MyoPro sales on a lump sum basis. The rule became effective on January 1, 2024.

•
On February 29, 2024, CMS published final payment determinations for the HCPCS codes describing our products which are L8701, for the MyoPro Motion W, and L8702, for the MyoPro Motion G, which became effective on April 1, 2024. These fees were subsequently updated to approximately $34,970 for the Motion W and approximately $68,800 for the Motion G, effective January 1, 2025. These fees are subject to annual inflationary adjustments.

•
On April 30, 2025, we introduced an enhanced version of our flagship product, now known as the MyoPro 2x in the United States.

Recent Developments

Equity Offerings

On December 6, 2024, we completed a public offering, selling 3,450,000 shares at $5.00 per share, generating net proceeds after fees and expenses of approximately $15.8 million. On January 19, 2024 we completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. Each pre-funded warrant in the above offerings entitles the holder to one share of common stock upon exercise at a nominal exercise price of $0.0001 per share. See section titled “Liquidity” for further discussion.

Term Loan Facility

On November 4, 2025 (“the Closing Date”), we entered into a Loan and Security Agreement with Avenue which provides us $17.5 million in committed funding under two tranches. The first tranche of $12.5 million was funded on the Closing Date. The remaining $5.0 million becomes available at our discretion between 12 and 18 months from the Closing Date, subject to maintaining compliance with covenants. We are paying interest only on the term loan for a period of 18 months from the Closing Date, which could be extended to 24 months if we borrowed under the second tranche. After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments. The term loan matures on June 1, 2029. Proceeds from this loan were used to repay the outstanding borrowings under the credit facility with Silicon Valley Bank and to pay fees and expenses, with the remainder being used for general corporate purposes

China Joint Venture

49

Table of Contents

In November 2025, we were notified that Ryzur Medical filed for bankruptcy in China and is in the process of being liquidated. As a result, the operations of the JV Company are now severely limited. Chinaleaf Capital, a minority investor in the JV Company, is currently leading the process of restructuring the JV Company and raising additional capital in order to re-start normal operations. According to the terms of the JV Contract, the sale of shares in the JV Company will not dilute our ownership. We cannot provide any assurance that we will accept any terms and conditions that new investors, if any, will require and we may exercise our right to terminate the joint venture in the future.

All assets associated with our investment in the JV Company were either reserved or written off in prior periods. As a result, these events had no impact on our financial statements for the year ended December 31, 2025.

Results of Operations

We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue in 2026. Our financial performance in 2025 reflected our ability to be reimbursed by Medicare for providing the MyoPro to their beneficiaries, as well as challenges around marketing efficiency and patient acquisition which increased Cost Per Pipeline Add. Our plan for 2026 is to begin to pivot away from relying on direct to patient advertising to generate revenues and invest in generating revenues from recurring sources, including the MyoConnect referral program and from O&P providers in the U.S. and Germany, while implementing marketing initiatives to reduce Cost Per Pipeline Add in the direct billing channel and minimizing the growth of fixed expenses.

Comparison of the year ended December 31, 2025 to the year ended December 31, 2024

The following table sets forth our revenue, gross profit and gross margin for each of the years presented.

[[GREPCENT_TABLE]]
[["","","Years Ended December 31,","","","Year-to-year change"],["","","2025","","","2024","","","$","","","%"],["Total revenue","","$","40,928,042","","","$","32,551,199","","","$","8,376,843","","","","26","%"],["Cost of revenue","","","14,039,718","","","","9,365,856","","","","4,673,862","","","","50","%"],["Gross profit","","$","26,888,324","","","$","23,185,343","","","$","3,702,981","","","","16","%"],["Gross margin","","","65.7","%","","","71.2","%","","","","","","(5.5","%)"]]
[[/GREPCENT_TABLE]]

Revenues

We derive revenue primarily from providing devices directly to patients and billing insurance companies directly. We also sell our products to O&P providers in the United States. Europe and Australia, to the VA and evaluation units to rehabilitation hospitals. Though we increasingly provide devices directly to patients, we sometimes utilize the clinical services of O&P providers for which they are paid a fee.

We expect that our revenues will continue to grow in 2026, primarily as a result of investments to grow revenues from recurring sources, including generating patient referrals un

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/MYO/mda/fy2025/
All MD&A years: /company/MYO/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/MYO/mda/fy2024/): filed 2025-03-10; accession 0000950170-25-036349 (https://www.sec.gov/Archives/edgar/data/1369290/000095017025036349/myo-20241231.htm)
- [FY 2023 MD&A](/company/MYO/mda/fy2023/): filed 2024-03-08; accession 0000950170-24-028326 (https://www.sec.gov/Archives/edgar/data/1369290/000095017024028326/myo-20231231.htm)
- [FY 2022 MD&A](/company/MYO/mda/fy2022/): filed 2023-03-13; accession 0000950170-23-007560 (https://www.sec.gov/Archives/edgar/data/1369290/000095017023007560/myo-20221231.htm)
- [FY 2021 MD&A](/company/MYO/mda/fy2021/): filed 2022-03-11; accession 0001564590-22-009827 (https://www.sec.gov/Archives/edgar/data/1369290/000156459022009827/myo-10k_20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/MYO.md · JSON record: /company/MYO.json · verified financials: /company/MYO/financials.json / /company/MYO/financials.csv · machine TOC for the whole site: /llms.txt